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BaCKgRoUND aND aIMS: Polycystic liver diseases 
(PLDs) are genetic disorders characterized by progressive de-
velopment of symptomatic biliary cysts. Current surgical and 
pharmacological approaches are ineffective, and liver trans-
plantation represents the only curative option. Ursodeoxycholic 
acid (UDCA) and histone deacetylase 6 inhibitors (HDAC6is) 
have arisen as promising therapeutic strategies, but with par-
tial benefits.
appRoaCH aND ReSUltS: Here, we tested an ap-
proach based on the design, synthesis, and validation of a 
family of UDCA synthetic conjugates with selective HDAC6i 
capacity (UDCA-HDAC6i). Four UDCA-HDAC6i conju-
gates presented selective HDAC6i activity, UDCA-HDAC6i 
#1 being the most promising candidate. UDCA orientation 
within the UDCA-HDAC6i structure was determinant for 
HDAC6i activity and selectivity. Treatment of polycystic rats 
with UDCA-HDAC6i #1 reduced their hepatomegaly and 
cystogenesis, increased UDCA concentration, and inhibited 
HDAC6 activity in liver. In cystic cholangiocytes UDCA-
HDAC6i #1 restored primary cilium length and exhibited 
potent antiproliferative activity. UDCA-HDAC6i #1 was ac-
tively transported into cells through BA and organic cation 
transporters.
CoNClUSIoNS: These UDCA-HDAC6i conjugates open a 
therapeutic avenue for PLDs. (Hepatology 2021;73:186-203).
Polycystic liver diseases (PLDs) constitute a heterogeneous group of genetic disorders characterized by progressive development of 
multiple fluid-filled biliary cysts (>10), which are 
the main cause of morbidity.(1,2) PLDs are inherited 
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as dominant (i.e., autosomal-dominant polycystic 
liver disease [~1:100,000 prevalence] and autoso-
mal-dominant polycystic kidney disease [ADPKD; 
~1:1,000 prevalence]) or recessive (i.e., autosomal- 
recessive polycystic kidney disease [ARPKD; 
~1:20,000 prevalence]) forms. Depending on the gene 
affected and the type of mutation, cysts arise exclu-
sively in liver (i.e., protein kinase C substrate 80K-H, 
translocation protein SEC63 homolog, low-density 
lipoprotein receptor-related protein 5, neutral alpha- 
glucosidase AB [GANAB], protein transport protein 
Sec61 subunit beta, and asparagine-linked glycosyla-
tion 8 genes) or also in kidneys (polycystic kidney 
disease [PKD]; PKD1, PKD2, GANAB, and polycys-
tic kidney and hepatic disease 1 [PKHD1] genes).(1,2) 
Available treatments are mainly surgical resection 
of symptomatic cysts and systemic treatment with 
somatostatin analogues, which show short-term and 
modest benefits. Liver transplantation represents 
the only curative option.(1,2) Therefore, therapeutic 
approaches based on a deeper understanding of the 
molecular mechanisms of pathogenesis are required. 
Cystogenesis in PLDs is characterized by diverse 
functional alterations in the bile duct cells (i.e., chol-
angiocytes),(1,2) which include hyperproliferation and 
-secretion, increased matrix metalloproteolytic activ-
ity, changes in microRNA expression patterns, and 
morphological and functional alterations of the pri-
mary cilium, a sensory organelle. These pathological 
events are intracellularly mediated by increased levels 
of cAMP and decreased Ca2+, their regulation being 
postulated as a potentially therapeutic target.(1-3)
The use of somatostatin analogues aimed to 
down-regulate the characteristic increased intra-
cellular cAMP levels in cystic cholangiocytes, and 
their resultant hyperproliferation and -secretion, is 
the only current pharmacological option with lim-
ited therapeutic benefits and several side effects. 
Ursodeoxycholic acid (UDCA), an endogenous bile 
acid (BA) with choleretic and hepatoprotective prop-
erties, is able to halt hepatic cystogenesis in exper-
imental models (in vitro and in vivo in PCK rats) 
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and patients with advanced ADPKD, by normaliz-
ing intracellular calcium levels in cystic cholangio-
cytes and by clearing the liver from accumulation of 
cytotoxic and promitotic BAs.(4,5) Of note, UDCA 
treatment improved symptomatology in both PCK 
rats and patients with ADPKD.(4,5) On the other 
hand, the therapeutic potential of histone deacety-
lase (HDAC) 6 (HDAC6) inhibitors (HDAC6is), 
such as tubastatin-A and ACY1215, for treat-
ment of both PLDs and PKDs has been described 
in vitro(6-8) and in vivo,(9) given that cystogenesis 
is characterized by cytoplasmic overexpression of 
HDAC6, which promotes the deacetylation of α- 
tubulin, one of the main structural proteins of the 
primary cilium.(9) Consequently, decreased acetyl-
ation of α-tubulin results in morphological and 
functional abnormalities of the primary cilium and 
promotes cell proliferation.(9)
The hypothesis of the present study was that 
UDCA, owing to its particular structural features 
and ability to conjugate taurine or glycine, could be 
an excellent external van der Waals cap molecule 
for the design of HDAC6is (i.e., UDCA-HDAC6i 
[synthetic conjugate of ursodeoxycholic acid]). It is 
known that preorganized macrocyclic systems can 
exhibit high noncovalent binding constants with the 
area close to the rim that connects the active sites of 
HDACs with the surface of these enzymes.(10,11) We 
reasoned that a polycyclic molecule such as UDCA 
could be a suitable conformationally restricted ana-
logue to these macrocyclic systems. This polycyclic 
moiety should be covalently bound to a spacer able 
to fill the tube that connects the active site of the 
enzyme with the rim.(12) Finally, this kind of HDAC 
inhibitor (HDACi) should include a chelating group 
able to bind the Zn2+ present in the active site.(13) The 
presence of UDCA in the UDCA-HDAC6i structure 
could also improve the hepatotropism of these mol-
ecules and their targeting toward cystic cholangio-
cytes.(14-16) Moreover, UDCA-HDAC6i could retain 
some of the previously observed therapeutic benefits 
of UDCA on PLDs, and the abundance of UDCA in 
the BA pool could be increased because of intestinal 
reuptake after UDCA-HDAC6i hydrolysis by the gut 
microbiota.(17) In contrast to conventional HDAC6i, 
UDCA-HDAC6i biotransformation is not expected 
to result in toxic intermediate molecules. Therefore, 
this strategy would provide a single-molecule–based 
combination therapy.
Materials and Methods
DoCKINg aND HoMology 
MoDelINg
The X-ray structure of the human HDAC6 catalytic 
domain 2 was obtained from the RCSB Protein Data 
Bank (PDB entry: 5EDU). The protein structure was 
optimized and minimized using the protein prepa-
ration wizard software included in the Maestro 10.4 
package (Schrödinger, LLC, New York, NY). Ligands 
were represented with a Maestro graphic interface 
and optimized with the LigPrep tool included in the 
Maestro 10.4 package. Flexible docking experiments 
were carried out using Glide software included in the 
Maestro 10.4 package, using extra precision mode to 
maximize accuracy of the obtained results. Obtained 
structures and binding-predicted energies were ana-
lyzed using Maestro and Pymol graphic interfaces. 
The homology model of rat HDAC6 catalytic domain 
2 (Uniprot entry: A0A0G2QC41) was generated 
based on human HDAC6 catalytic domain 2 (PDB 
entry: 5EDU) with Prime software, also included in 
the Maestro 10.4 package (Schrödinger, LLC). For 
docking studies, the same procedure as for the human 
HDAC6 catalytic domain 2 was followed.
HDaC aCtIVIty aSSayS
HDAC activity assays were performed using 
acetylated peptide substrates labeled with 7-amino- 
4-methylcoumarin at Reaction Biology Corporation 
(Malvern, PA). All the enzymes and substrates used 
are summarized in Supporting Table  S9, and the 
details of the assays and protocols are described in the 
Supporting Information.
tReatMeNt oF pCK RatS WItH 
HDaC6i-UDCa #1
The PCK rat (Charles River Laboratories Inc, 
Wilmington, MA) is an animal model of ARPKD, 
presenting a mutation in the human orthologue Pkhd1 
gene and spontaneously developing both hepatic and 
renal cysts. Both wild-type (WT; n  =  12) and PCK 
rats (n  =  20) were 8  weeks old at the beginning of 
the experiment. PCK rats were randomized into 
HDAC6i-UDCA #1–treated (n  =  8; 15  mg/kg/d by 
oral gavage for 5  months) and nontreated (n  =  12) 
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groups. After treatment, animals were euthanized and 
blood was collected, and serum was further isolated 
to determine biochemical markers of liver and kidney 
disease. Liver and kidneys were collected, weighted, 
and either fixed in 4% paraformaldehyde or stored at 
−80°C for further analysis. All in vivo experimental 
procedures were performed according to the Guide 
for the Care and Use of Laboratory Animals and 
approved by the Ethics Committee of Biodonostia 
Health Research Institute.
Ba MeaSUReMeNt
Concentrations of BA species in liver, bile, periph-
eral, and portal blood were measured after methanol 
precipitation/extraction by high-performance liquid 
chromatography with tandem mass spectrometry 
using a modification(18) of a described method.(19)
CellS aND CUltURe 
CoNDItIoNS
Primary cultures of normal and cystic human chol-
angiocytes, previously isolated and characterized by 
our group,(20) were used for in vitro assays. Culture 
conditions, and the three-dimensional (3D) cul-
turing of cystic cholangiocytes, are described in the 
Supporting Information.
eXpeRIMeNtal 
oVeReXpReSSIoN oF HUMaN 
tRaNSpoRteRS IN CellS aND 
tRaNSpoRt aSSayS
Experimental overexpression of the human trans-
porters in cells and transport assays were performed as 
described in the Supporting Information.
qpCR
Total RNA extraction and retrotranscription and 
further qPCRs were performed as described in the 
Supporting Information. All the primer sequences are 
summarized in Supporting Table S11.
IMMUNoBlottINg
Analysis of protein expression was performed as 
described in the Supporting Information and using 
the antibodies listed in Supporting Table S12.
pRIMaRy CIlIa aNalySIS
Primary cilia length and number of ciliated chol-
angiocytes were analyzed by immunofluorescence as 
described in the Supporting Information.
Cell pRolIFeRatIoN
Evaluation of proliferation in cystic cholangiocytes 
was carried out as described in the Supporting Data.
StatIStICal aNalySIS
GraphPad Prism software was applied for sta-
tistical analysis (version 6; GraphPad Software Inc., 
La Jolla, CA). Data are expressed as mean  ±  SEM. 
Unless otherwise indicated, for comparisons between 
two groups, a two-tailed parametric Student t test or 
nonparametric Mann-Whitney U test were used. In 
all cases, measurements were taken from distinct sam-
ples (i.e., cell cultures, tissue samples, and individual 
cystic cholangioids). Statistically significant data, rep-
resented as asterisks (*, **, and ***), denote a P value 
<0.05, <0.01, and <0.001, respectively.
Results
SyNtHetIC UDCa CoNJUgateS 
SeleCtIVely INHIBIt HDaC6 
aCtIVIty
We applied our previously described HDAC inhi-
bition model(21) to the X-ray structure of the catalytic 
domain 2 of human HDAC6 (PDB code: 5EDU)(22) 
(Fig.  1A). HDAC6 active sites can be schematically 
described as an ensemble of external shallow cavi-
ties connected through a hydrophobic channel with a 
Zn2+-containing catalytic site. Following this general 
model, we designed a family of synthetic UDCA con-
jugates, in which the steroid skeleton of UDCA acted 
as the external van der Waals cap of the inhibitor, fol-
lowed by a number of different hydrophobic spacers 
ended on a Zn2+ chelating group (Fig. 1A).
Chemical synthesis of the UDCA-HDAC6i mol-
ecules (Fig.  1B) started with the coupling reaction 
of UDCA (1) with amines (2) to yield amide esters 
(3). Cleavage of the methoxy groups of adducts (3) 
and in situ reaction with hydroxylamine permitted the 
isolation and characterization of UDCA-hydroxamic 
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acids UDCA-HDAC6i #1, #3-6, and #10, which 
possess different lengths and stereoelectronic fea-
tures. Alternatively, hydrolysis of esters (3) permitted 
the preparation of acid (4). Subsequent coupling with 
orthophenylenediamines (7) yielded amide candidates 
UDCA-HDAC6i #7 and #8. The spacer between the 
chelating group and the UDCA component was elon-
gated by means of an additional hydrolysis-coupling 
sequence (5), thus yielding esters (6) whose cleav-
age and reaction with hydroxylamine permitted the 
A
B
FIg. 1. Design, synthesis, in silico prediction, and in vitro characterization of the HDACi activity of UDCA synthetic conjugates. 
(A) Scheme of the designing of UDCA-HDAC6i molecules based on HDAC6 structure. (B) Chemical synthesis of the 10 different 
UDCA-HDAC6i molecules. (C) Docking studies. Graphical representation of the biding modes of UDCA-HDAC6 is (yellow #9, 
green #1, blue #2, and grey #4, #10, #6, #5, and #3) to the active site of human AC6 CD2. Dashed yellow lines represent hydrogen 
b nds between hydroxyl groups of UDCA and amin  acids of the protein surface. Table isplays the predicted bindi g energies for 
UDCA-HDAC6is. (D) Representative immunoblotting of acetylation (Ac) levels of α-tubulin and H3K9 after 24 hours of treatment 
with 2 μM of each compound. (E) Experimental validation of the in silico model. Correlation between the predicted biding energies 
(HDAC6i) and levels (%) of acetylated α-tubulin in PLD cells treated with each UDCA-HDAC6i. Abbreviations: Asp567, aspartate; 
DMF, N,N-dimethylformamide; His, histidine; Leu, leucine; Ser, serine; TBTU, N,N,N′,N′-tetramethyl-O-(benzotriazol-1-yl)uronium 
tetrafluoroborate; Trp, tryptophan; XP Gscore, XP GlideScore.
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isolation and characterization of candidates UDCA-
HDAC6i #2 and #9.
The potential HDAC6 inhibitory capacity of this 
family of UDCA synthetic conjugates was first evalu-
ated in silico with a docking model (Fig. 1C). Significant 
binding affinities to HDAC6 were predicted for eight 
of these compounds, with UDCA-HDAC6i #1, #2, 
and #9 being the ones that displayed the highest 
energy scores (−8.3, −7.9, and −9.4  kcal/mol, respec-
tively; Fig.  1C). Interestingly, these three compounds 
oriented the hydrocarbon skeleton of UDCA toward 
the same region of the protein surface (Fig.  1C). We 
decomposed the total binding energy of each synthetic 
derivative component into the contribution of the dif-
ferent descriptors (i.e., hydrogen bonds, van der Waals 
interactions) to the overall score (Supporting Tables S1 
and S2A,B). Importantly, the contribution of UDCA 
to the final binding energy of UDCA-HDAC6i #1, 
#2, and #9 was approximately one-third of the total 
value, and was mainly integrated by van der Waals 
interactions, and hydrogen bonds established by the 
two hydroxyl groups of the steroid skeleton of the BA 
(Fig. 1C; Supporting Tables S1 and S2A,B).
Given that cytoplasmic levels of acetylated 
α-tubulin in cholangiocytes are directly linked to the 
degree of HDAC6 expression and activity,(9,23) cystic 
human cholangiocytes in culture were incubated with 
UDCA-HDAC6i and protein expression of acetyl-
ated α-tubulin was measured by immunoblotting. 
In addition, acetylation levels of lysine 9 of nuclear 
histone 3 (H3K9) were assessed as a selectivity test 
(negative control). The results (Fig. 1D) revealed that, 
at low concentration (2  μM), UDCA-HDAC6i #1, 
#2, #6, and #9 increased acetylated α-tubulin levels in 
cystic cholangiocytes, without affecting H3K9 acetyl-
ation, thus indicating a selective inhibitory activity on 
HDAC6. In contrast, UDCA-HDAC6i #8 increased 
H3K9 acetylation, without affecting α-tubulin acetyl-
ation. Of note, the predicted binding affinity (i.e., 
energy values by docking) of the aforementioned 
UDCA-HDAC6i for HDAC6 and their effect on 
HDAC6-dependent acetylated α-tubulin levels in 
cystic cholangiocytes showed significant correlation 
(r2 = 0.8031), supporting the accuracy of the compu-
tational approach used here (Fig. 1E).
Next, inhibitory capacity of UDCA-HDAC6i #1, 
#2, #6, #8, and #9 on purified histone deacetylase 1 
(HDAC1) and HDAC6 enzymes was measured by 
monitoring the dose-dependent deacetylation of a 
fluorogenic acetylated peptide (Fig.  2A). UDCA-
HDAC6i #1, #2, #6, and #9 displayed low half max-
imal inhibitory concentration (IC50) values (58, 56.1, 
82.1, and 4.26  nM, respectively) for HDAC6 inhi-
bition, concomitantly with a high degree of selec-
tivity, particularly in the case of compounds #1, #2, 
and #9 (Fig.  2A). As expected, UDCA-HDAC6i 
#8 showed both high inhibitory activity and selec-
tivity for HDAC1 (IC50  =  140  nM; Fig.  2A). 
Importantly, UDCA itself did not exhibit any direct 
HDAC inhibitory activity; however, its formal cou-
pling with the separate spacer-chelating component, 
4-(aminomethyl)-N-hydroxybenzamide hydrochloride 
[Fig. 2B, chelating-spacer (8)], to form UDCA-
HDAC6i #1 significantly increased (~12-fold) the 
HDAC6 inhibitory capacity of the chemical entity 
(IC50  =  689 vs. 58  nM; Fig.  2B), highlighting the 
active contribution of UDCA to the inhibitory activ-
ity of the UDCA-HDAC6is (Fig. 2B and Supporting 
Fig. S1). In addition, the effect of UDCA-HDAC6i 
#1 and #2 was also evaluated on purified HDAC2-5 
and HDAC7-11 enzymes, showing quite similar 
inhibitory capacity to HDAC1 and significantly less 
compared to HDAC6 (Supporting Table S3). Of note, 
the 3D structural alignment of the catalytic domains 
of human HDAC1, 2, 3, 4, 7, and 8 and zebrafish 
HDAC10 (PDB entries: 5ICN, 6G3O, 4A69, 4CBT, 
3ZNR, 5VI6, and 5TD7) with our docking model of 
human HDAC6 CD2 revealed that although all the 
analyzed HDAC active sites fitted well to the general 
model previously mentioned (Fig. 1A), they possessed 
important differences in the architectures of their 
outer rims, hydrophobic channels, and catalytic sites 
(Fig.  2C). In this regard, we found particularly rel-
evant the high degree of sequence disparity between 
HDAC6 and the rest of the isoforms in the surface 
area occupied by UDCA in the three most active/
selective inhibitors (Supporting Fig. S2), resulting in 
the absence of this cavity in the other HDAC iso-
forms, whereas the other two cavities occupied by 
less active/selective UDCA-HDAC6is (e.g., UDCA-
HDAC6i #6) remained almost intact (Fig.  2D and 
Supporting Fig. S2).
Once the affinity and selectivity for HDAC6 
inhibition was confirmed in four of the synthesized 
UDCA-HDAC6i molecules, we generated a homol-
ogy model of the catalytic domain 2 of rat HDAC6 
in order to predict the inhibitory capacity of these 
compounds between species (Supporting Fig.  S3). 





FIg. 2.  In vitro and in silico characterization of the critical role of UDCA for the HDAC6 inhibitory activity and selectivity of UDCA-
HDAC6is. (A) Dose-response curves of the inhibitory activity of UDCA-HDAC6i #1 (n = 9), #2 (n = 9), #6 (n = 3), #8 (n = 3), and #9 (n = 3) 
on HDAC6 and HDAC1. For curve fitting and IC50 calculation, log (inhibitor) versus normalized response with variable slope equation 
was used in GraphPad software (version 6; GraphPad Software Inc., La Jolla, CA). Extended information about HDAC IC50 values is 
provided in Supporting Table S3. (B) Comparison of the IC50 values of UDCA-HDAC6i #1 and 4-(aminomethyl)-N-hydroxybenzamide 
hydrochloride (8) for HDAC6 and graphical representation of the main interactions taking place in the binding of UDCA-HDAC6i #1 to 
the catalytic domain 2 of HDAC6 (hydrogen bonds in purple and π-π stacking interactions in green). Black arrows point to the two hydroxyl 
groups of UDCA within UDCA-HDAC6i #1 and the hydrogen bonds established between these and tryptophan 496 and histidine 560 of 
the catalytic domain 2 of human HDAC6. (C) Cross-sectional view of 3D-aligned active sites of different HDAC isoforms (HDAC1, 2, 
3, 4, 6, 7, and 8 and zebrafish HDAC10 [PDB entries: 5ICN, 6G3O, 4A69, 4CBT, 5EDU, 3ZNR, 5VI6, and 5TD7]). (D) 3D structural 
alignments of the docking model for the catalytic domain 2 of human HDAC6 with the catalytic domains of different HDAC isoforms. In 
blue, surface region of each isoform aligned to the cavity in which the three most active/selective UDCA-HDAC6is accommodate UDCA 
in HDAC6. Abbreviations: Gly, glycine; His, histidine; ND, not determined; Phe, phenylalanine; Ser, serine; Trp, tryptophan.
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Sequence alignment of the catalytic domains of both 
species revealed an identity of 88.4%. Importantly, as 
for the human HDAC6, UDCA-HDAC6i #1, #2, 
and #9 were the compounds with the highest bind-
ing energies in the rat homology model (Supporting 
Fig.  S3), suggesting that their inhibitory potential 
would be maintained in the rat. This points to a direct 
correspondence between our results and those expected 
in humans.
Next, UDCA-HDAC6i #1 was selected for further 
in vivo analysis (Supporting Table  S4). In particular, 
we hypothesized that the UDCA-HDAC6i molecules 
could benefit from the intrinsic hepatotropic features 
of UDCA, concentrating them preferentially into the 
liver and in cystic cholangiocytes after oral administra-
tion and gastrointestinal absorption. In addition, these 
molecules could also be reabsorbed through the entero-
hepatic/bile circulation. In this regard, we applied the 
QikProp software included in the Maestro package 10.4 
(Schrödinger, LLC) to in silico predict several pharmaco-
kinetic parameters for all UDCA-HDAC6i molecules, 
obtaining considerably better values for UDCA-
HDAC6i #1 than for the other three active candidates 
in terms of oral absorption. UDCA-HDAC6i #1 dis-
played values within the recommended range for all the 
parameters analyzed, whereas UDCA-HDAC6i #2 and 
#9 presented several potential limitations.
UDCa-HDaC6i #1 HaltS  
Hepato- aND NepHRoMegaly 
IN pCK RatS
The therapeutic value of UDCA-HDAC6i #1 
was evaluated in PCK rats (Pkhd1 mutant), an ani-
mal model for hepatorenal cystogenesis (Fig. 3).(24,25) 
Eight-week-old PCK rats were treated with UDCA-
HDAC6i #1 (15 mg/kg/d by oral gavage) for 5 months. 
Remarkably, the characteristic hepato- and nephromeg-
aly that PCK rats develop over time was significantly 
reduced after treatment with UDCA-HDAC6i #1. 
Liver- and kidney-to-body weight ratios were also 
reduced compared to untreated PCK rats (Fig. 3A,B, 
respectively). These effects were associated with an 
improvement of both liver and kidney functions, as 
reflected by increased serum albumin and reduced urea 
levels, respectively (Fig.  3A,B). At the end of treat-
ment, UDCA-HDAC6i #1 was detected in liver, bile, 
and portal and peripheral blood, but was particularly 
abundant in bile (Fig.  3C). Moreover, an increase in 
acetylated α-tubulin levels was found in both liver 
and kidney of animals receiving UDCA-HDAC6i #1 
compared to untreated PCK rats (Fig. 3D).
UDCa-HDaC6i #1 MoDUlateS 
tHe Ba pool aND INCReaSeS 
leVelS oF UNCoNJUgateD UDCa 
IN pCK RatS
BA concentrations and pool composition were 
determined in liver, bile, and both portal and periph-
eral blood. Consistent with previous reports,(4,5) total 
BA concentrations in both liver and peripheral blood 
were higher in PCK rats than in normal animals. 
These values were not modified in PCK rats treated 
with UDCA-HDAC6i #1 (Fig.  4). Moreover, total 
BA concentrations in portal blood and bile were simi-
lar in treated and untreated groups (Fig. 4). However, 
some differences in composition of the BA pool were 
found. Thus, the described(4,5) decreased UDCA lev-
els in liver of PCK rats were restored upon UDCA-
HDAC6i #1 treatment (Fig.  4). Similarly, increased 
levels of UDCA were found in portal and peripheral 
blood, as well as in bile, of PCK rats treated with 
UDCA-HDAC6i #1 compared to both normal and 
PCK untreated animals (Fig. 4). Likewise, a normal-
ization of major unconjugated bile acids (i.e., cholic 
acid [CA], α/β murocholic acid, and sulpholithocholic 
in liver; CA and hyodeoxycholic acid in bile) in 
treated PCK animals was found (Fig.  4; Supporting 
Tables S6 and S7).
UDCa-HDaC6i #1 HaltS lIVeR 
CyStogeNeSIS IN VIVO, 
ReStoReS pRIMaRy CIlIUM 
leNgtH, aND INHIBItS 
CyStIC CHolaNgIoCyte 
pRolIFeRatIoN
Histological analysis of the cholangiocyte marker, 
cytokeratin 19 (CK19), revealed a reduction in mag-
nitude of cystic areas in liver of UDCA-HDAC6i 
#1–treated animals compared to PCK untreated rats 
(Fig.  5A). HDAC6 inhibitory activity of UDCA-
HDAC6i #1 increased (64%) the primary cilium 
length of cystic cholangiocytes and the number of 
ciliated cholangiocytes (182%) in liver of the treated 
animals (Fig.  5B); similarly, in vitro, UDCA-
HDAC6i #1 increased levels of acetylated α-tubulin 
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FIg. 3. Effect of UDCA-HDAC6i #1 on hepatorenal cystogenesis in vivo. (A) Representative liver images from a normal rat, as well 
as nontreated and UDCA-HDAC6i #1–treated PCK rats. Graphical representation of relative comparisons of liver weight, total body 
weight, liver/body weight ratio, and serum albumin concentration in the three experimental groups. A statistical unpaired two-tailed 
t-test analysis was applied to determine significance in all cases, with the exception of PCK treated versus nontreated liver/body weight in 
which an unpaired one-tailed t-test analysis was applied. (B) Representative kidney images from a normal rat, as well as nontreated and 
UDCA-HDAC6i #1–treated PCK rats. Graphical representation of relative comparisons of kidney weight, kidney/body weight ratio, and 
serum urea concentration in the three experimental groups. A statistical unpaired two-tailed t test was applied to determine significance. 
(C) Analysis of UDCA-HDAC6i #1 pharmacokinetics. Graph represents the bioavailability profile of UDCA-HDAC6i #1 in blood 
(n = 8), liver (n = 8), bile (n = 7), and peripheral blood (n = 8) during chronic oral administration. An unpaired two-tailed t test was applied 
to assess for significance. (D) Representative immunoblotting of the acetylated (Ac) α-tubulin levels in liver and kidney of treated (n = 8) 
and nontreated (n = 12) PCK rats. Graph represents the relative amount of acetylated α-tubulin in liver and kidney using total tubulin 
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(Fig.  5C) and restored the primary cilium length 
of cystic cholangiocytes (~40% increase; Fig.  5D), 
but induced no changes in normal cholangiocytes 
(Fig. 5D).
Given that the primary cilium promotes epithelial 
cell polarity and prevents cell-cycle initiation,(26,27) we 
analyzed the effect of UDCA-HDAC6i #1 on pro-
liferation/expansion of cystic cholangiocytes. UDCA-
HDAC6i #1 inhibited the 3D growth of cystic 
cholangioids compared to control conditions (Fig. 6A). 
Similarly, UDCA-HDAC6i #1 inhibited two-di-
mensional (2D) cystic cholangiocyte proliferation in 
FIg. 4. BA pool in portal blood, liver, bile, and peripheral blood. Bar graphs represent total BA concentration, unconjugated UDCA 
concentration, and relative abundance of conjugated BAs in each biological sample. Quantitative and statistical information about the 
relative abundancy of single BAs is depicted in Supporting Tables S5-S8. A statistical unpaired two-tailed t test was applied to determine 
significance. Abbreviation: ns, not significant.
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vitro in a dose-dependent manner (Fig.  6B), which 
was associated with phosphorylated extracellular sig-
nal-regulated kinase (ERK) 1/2 (pERK1/2) regulation 
(Fig. 6C). Importantly, this antiproliferative effect was 
significantly higher than that observed upon com-
bined treatment with UDCA plus the separate spacer- 
FIg. 5. Effect of UDCA-HDAC6i #1 on liver cystogenesis and primary cilium length. (A) Representative images of hematoxylin/eosin 
staining (scale bar = 250 µm) and CK19 immunohistochemistry (scale bar = 100 µm). Graph represents the cystic area relative to total 
tissue area of individual hepatic lobes (three for each animal). A statistical unpaired two-tailed t test was applied to determine significance. 
(B) Representative images of liver sections from untreated and UDCA-HDAC6i #1–treated PCK rats. Cilia are labeled with antibodies 
against acetylated (Ac) α-tubulin (green) and nuclei are stained (blue) with DAPI. Bar graphs represent length of primary cilia and percentage 
of ciliated cholangiocytes. White asterisks indicate cyst lumen. Cysts were randomly selected from untreated (n = 6) and treated rats (n = 9). 
A statistical unpaired two-tailed t test was applied to determine significance. Data are expressed as mean ± SEM. (C) Representative 
immunoblotting of the effect of increasing doses of UDCA-HDAC6i #1 in levels of acetylated α-tubulin in cultured PLD cholangiocytes. 
GAPDH was used as normalizing control. (D) Representative immunofluorescence images of acetylated α-tubulin in cholangiocytes 
(primary cilium in green and nucleus in blue stained with DAPI). Bar graph represents the mean cilia length of normal (nontreated [n = 23] 
and 2 µM of UDCA-HDAC6i #1 treated [n = 21]) and PLD (nontreated [n = 30] and 2 µM of UDCA-HDAC6i #1 treated [n = 27]) 
human cholangiocytes. A statistical one-way ANOVA was used. Abbreviations: ANOVA, analysis of variance; DAPI, 4′,6-diamidino-2-
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chelating component (8) (Fig.  6B), demonstrating 
that UDCA-HDAC6i #1 has intrinsic properties.
HepatotRopIC pRopeRtIeS oF 
UDCa-HDaC6i #1
To investigate the mechanism of UDCA-
HDAC6i #1 uptake by cystic cholangiocytes (i.e., 
passive diffusion or membrane protein trans-
port), time-dependent compound internalization 
was measured in cystic cholangiocytes exposed to 
UDCA-HDAC6i #1 at 4°C or 37°C, respectively. 
Importantly, significant differences in uptake ratios 
at both temperatures were observed, suggesting that 
an important part of UDCA-HDAC6i #1 internal-
ization occurs through plasma membrane proteins 
(37°C), rather than by passive diffusion across the 
lipid bilayer (4°C; Fig.  7A). Therefore, in order 
to assess the specific transporters involved in the 
UDCA-HDAC6i #1 internalization process, we 
FIg. 6. Effect of UDCA-HDAC6i #1 on proliferation of 2D- and 3D-cultured PLD cholangiocytes. (A) 3D culture in collagen type I 
of bile ducts/cysts isolated from PCK rats. Representative images and graph representing the relative circumferential area of nontreated 
(n = 20) and UDCA-HDAC6i #1–treated (n = 20; 10 µM) cystic cholangioids along time. (B) Proliferation of PLD cholangiocytes 
by flow cytometry. Bar graph represents the percentage of cell proliferation after 48 hours of treatment with 10 µM of UDCA (n = 7), 
100 µM of UDCA (n = 22), 2 µM of UDCA-HDAC6i #1 (n = 16), 10 µM of UDCA-HDAC6i #1 (n = 23), 10 µM of spacer chelating 
component (8) (n = 23), or combined treatment with 10 µM of UDCA + 10 µM of spacer chelating component (8) (n = 7) relative to 
control PLD cholangiocytes (n = 23) without treatment. (C) Representative immunoblotting of phosphorylated and total ERK1/2 protein 
levels from cell lysates of nontreated and UDCA-HDAC6i #1–treated PLD cholangiocytes. Graph represents the relative abundance of 
phosphorylated ERK1/2 in baseline (n = 5) and 2 µM (n = 5) or 10 µM (n = 5) of UDCA-HDAC6i #1–treated PLD cholangiocytes using 
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next used cell models experimentally overexpressing 
plasma membrane transporters in substrate compe-
tition assays (Supporting Fig. S4). The results indi-
cated that UDCA-HDAC6i #1 was transported by 
the organic cation transporters (OCTs), OCT1 and 
OCT3, (Fig. 7B) as well as by the sodium-dependent 
BA transporter (Na+-taurocholate cotransporting 
polypeptide), commonly expressed in hepatocytes 
(Supporting Fig. S5). In contrast, neither the apical 
sodium-dependent bile salt transporter expressed in 
cholangiocytes nor any of the assayed organic anion 
transporters (i.e., organic anionic transporting poly-
peptide [OATP] 1A2, OATP1B1, OATP1B3, and 
OATP2B1) mediated UDCA-HDAC6i #1 uptake 
(Supporting Fig.  S5). Interestingly, the analysis of 
expression (RT-qPCR) of these transporters marked 
up-regulation of OCT1 and OCT3 in cystic 
human cholangiocytes compared to normal controls 
(Fig. 7C). Furthermore, we confirmed by immuno-
histochemistry the expression (plasma membrane 
and cytoplasm) of OCT1 and OCT3 transport-
ers in cyst-lining cholangiocytes (and hepatocytes; 
Fig. 7D) of PCK rat liver tissue.
Discussion
Oral administration of UDCA is well tolerated, 
safe, and is currently the first-line therapy interna-
tionally approved for the treatment of primary bili-
ary cholangitis.(28) Chronic treatment with UDCA 
inhibits hepatic cyst growth in experimental models 
and also in a subset of patients with advanced PLD 
(CURSOR [Ursodeoxycholic Acid as Treatment 
for Polycystic Liver Disease] phase II clinical trial), 
improving their symptomatology.(4,5) On the other 
FIg. 7. Mechanisms of UDCA-HDAC6i #1 uptake into cells. (A) Time-course analysis of UDCA-HDAC6i #1 uptake in cystic 
cholangiocytes incubated with 100 µM of UDCA-HDAC6i #1 at 37°C or 4°C. A statistical unpaired two-tailed t test between both 
conditions at each time point was applied to determine significance. Data are expressed as mean ± SEM. (B) Bar graphs representing 
UDCA-HDAC6i #1 uptake in HepG2 or CHO Mock cells or stably expressing OCT1 (n  =  4) or OCT3 (n  =  5), respectively, in 
the presence or absence of quinine as a competing substrate. The paired two-tailed t test was used to assess statistical significance. 
(C) RT-qPCR analysis of mRNA expression of OCT1 and OCT3 transporters in normal (n = 6) and PLD (n = 6) human cholangiocytes. 
The RPL22 gene was used as the normalizing control. An unpaired two-tailed t test was applied to determine statistical significance. 
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hand, inhibition of HDAC6 activity has been pro-
posed as a therapeutic strategy for PLD.
The currently available HDAC6is do not show 
preferential targeting to the liver and, in particular, 
to biliary cells. Most HDAC6is developed to date 
comprise on their structure a hydrophobic linker 
ended on a Zn2+ chelating group that enters into the 
catalytic sites of HDAC6 and an external cap that 
accommodates on the surface cavities.(21) HDAC6i 
molecules usually contain aromatic peptide deriva-
tives and hydrocarbons acting as the closing cap of 
the inhibitor,(29-32) which are prone to be released 
into systemic circulation after their hepatic metabo-
lism. These residues have been largely demonstrated 
to be potentially toxic in humans. Most frequently 
observed manifestations of toxicity in clinical trials are 
fatigue, nausea, diarrhea, and cardiotoxicity, including 
ventricular arrhythmia, being the most worrisome 
adverse effects.(33,34) Considering these limitations 
for combination therapies,(35) and taking advantage of 
our experience in the designing of HDACis through 
innovative in silico docking analyses,(21) we hypoth-
esized that UDCA could be an appropriate external 
cap to reinforce the HDAC6 inhibitory capacity of 
the chelating groups, improve their hepatotropism, 
decrease their toxicity, and provide some of the afore-
mentioned UDCA benefits, because: (1) Our in sil-
ico docking experiments indicate that UDCA may 
actively contribute to reinforce the inhibitory poten-
tial of the hydrophobic linker + Zn2+ chelating group 
through the establishment of van der Waals interac-
tions and hydrogen bonds between the two hydroxyl 
groups present in the UDCA structure and the side 
chains of several amino acid residues located on the 
external cavities of HDAC6 close to the catalytic 
domains; (2) UDCA would provide hepatotropic 
features to these new UDCA-HDAC6i entities by 
promoting its enterohepatic transport through BA 
and/or OCTs; (3) UDCA is usually amidated with 
taurine (tauroursodeoxycholic acid) or glycine (gly-
coursodeoxycholic acid) by hepatocytes,(36,37) so this 
residue could be used for the formal conjugation to 
the spacer-chelating group; and (4) the gut microbi-
ome deconjugates the taurine or glycine residues of 
UDCA,(38) and, consequently, UDCA-HDAC6i pres-
ent in bile and entering the gut could be deconjugated 
by this process, resulting in a secondary increase of the 
enterohepatic levels of UDCA that would additionally 
inhibit PLD progression.
Data of the present study showed that UDCA 
has no HDAC inhibitory activity. However, its for-
mal coupling to the spacer-chelating component [Fig. 
2B, chelating-spacer (8)] (i.e., UDCA-HDAC6i #1) 
reduced 1 order of magnitude the IC50 value of [Fig. 
2B, chelating-spacer (8)] for HDAC6 inhibition. Of 
note, the three UDCA-HDAC6i molecules displaying 
the highest binding affinities to HDAC6 (i.e., UDCA-
HDAC6i #1, #2, and #9) were those containing one 
or two 1,4-phenylene spacers and hydroxamates as 
chelating groups. These three molecules oriented the 
hydrocarbon skeleton of UDCA toward the same 
region of the protein surface; indeed, the difference 
in binding energies with the other compounds, which 
accommodated UDCA in other surface cavities, was 
>3 kcal/mol. Importantly, predicted inhibitory activity 
of the UDCA-HDAC6i molecules on HDAC6 was 
further validated in both cystic cholangiocytes (i.e., 
acetylated α-tubulin expression) and enzymatic assays 
(specific HDAC6 vs. HDAC1 inhibitory activity) 
in vitro. Of note, replacement of the hydroxamic acid 
moiety of UDCA-HDAC6i #1 by the ortho-phenyl-
enediamine group present in UDCA-HDAC6i #8 
resulted in a complete switch in both the inhibitory 
potential and selectivity toward nuclear HDACs 
instead of HDAC6. These data highlight the accu-
racy of our in silico predictive model for molecules 
to inhibit HDAC6. In this regard, the importance 
of certain regions of the HDAC6 CD2 surface to 
determine inhibitor selectivity has been recently 
reported.(39) In accordance, structure alignment of 
different HDAC isoforms with our docking model 
revealed that the surface cavity occupied by UDCA in 
the three most HDAC6 active/selective compounds is 
not present in the other HDAC isoforms, whereas the 
cavity occupied by a still active, but much less selec-
tive, compound (i.e., UDCA-HDAC6i #6) remained 
fully accessible in all isoforms. All these data highlight 
the critical role that UDCA plays in dictating both 
activity and selectivity of UDCA-HDAC6is.
Once the inhibitory potential of the three best can-
didates was confirmed in human and rat HDAC6 by 
using a homology model of the catalytic domain 2, 
UDCA-HDAC6 #1 was selected for further in vivo 
and in vitro evaluation based on comparative analy-
sis of its selective HDAC6 inhibitory capacity (IC50), 
potential pharmacokinetics, and synthetic cost. Oral 
administration of UDCA-HDAC6i #1 to PCK rats 
considerably reduced the hepato- and nephromegaly 
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characteristic on these animals, as well as hepatic 
cystogenesis. Of note, this new molecule partially 
normalized the decreased serum levels of albumin, 
suggesting an improvement of liver function of these 
animals. In addition, levels of urea in serum were 
reduced upon treatment, indicating an improvement 
in renal function. On the other hand, no signs of tox-
icity were observed at biochemical and histological 
levels. The therapeutic effects of UDCA-HDAC6i 
#1 in the liver seem to be comparable (i.e., hepatic 
cystogenesis) or even superior (i.e., hepatomegaly) 
to the ones previously reported for UDCA(4,5) in the 
same animal model, even at substantially lower doses 
(i.e., 15 vs. 25  mg/kg/d for 5  months, respectively; 
Supporting Fig. S6). Moreover, in contrast to UDCA, 
UDCA-HDAC6i #1 also provides therapeutic effects 
on nephromegaly and renal function of PCK rats 
(Supporting Fig. S6).
At the histological level, increased acetylated 
α-tubulin was obtained in both liver and kidney of 
treated PCK rats compared to untreated animals, sup-
porting that UDCA-HDAC6i #1 is properly absorbed 
by the gut and is able to reach both the liver and kid-
neys, leading to HDAC6 inhibition. Importantly, this 
effect was mirrored by a significant increase in the 
number of ciliated cholangiocytes and primary cilium 
length in treated animals, providing important insights 
into the biological mechanisms behind the therapeutic 
effects. In line with this result, UDCA-HDAC6i #1 
restored the primary cilium length of cystic cholan-
giocytes in an acetylated α-tubulin–dependent man-
ner, whereas it had no effect on primary cilium length 
of normal cholangiocytes in vitro. Moreover, UDCA-
HDAC6i #1 inhibited the proliferation of cystic chol-
angiocytes cultured in 2D and 3D conditions, and this 
was more significant than the combined treatment 
with its forming components (i.e., UDCA + (8)) at 
the same concentration, indicating that UDCA rein-
forces the HDAC6 inhibitory activity of the spacer- 
chelating component. This observation was also 
accompanied by a significant reduction of ERK1/2 
phosphorylation, which mediates cystic cholangio-
cyte hyperproliferation.(3) All these data are consistent 
with the fact that the primary cilium acts as a check-
point inhibitor of the cell cycle, its restoration in cys-
tic cholangiocytes being a therapeutic strategy.(26,27,40)
Regarding BA metabolism, and similarly to our 
previous data with UDCA,(4) no significant changes 
in total BA concentration were observed between 
UDCA-HDAC6i #1–treated and nontreated animals. 
However, changes in certain BA species in bile, and to 
a lesser extent in liver, were found. Of note, increased 
levels of free UDCA in liver, bile, and serum were 
found in PCK rats treated with UDCA-HDAC6i #1, 
reinforcing the idea that biliary UDCA-HDAC6i #1 
could be further metabolized in the gut, leading to 
excision of the amide bond and thus resulting in the 
release of free UDCA that may enter the enterohe-
patic circulation in a second round and induce addi-
tional therapeutic benefit on hepatic cystogenesis.
As indicated above, two important limitations of 
currently available HDAC6is are their lack of selective 
affinity toward hepatic tissue as well as the presence of 
aromatic hydrocarbons or heterocycles in their struc-
tures,(29-32) which can be released as potentially toxic 
metabolites. Our data reveal that, after oral admin-
istration, UDCA-HDAC6i #1 accumulates preferen-
tially in liver and bile, rather than in peripheral blood, 
indicating a superior targeting to the liver and poste-
rior secretion into bile, thus potentially diminishing 
the off-target effects in other tissues. This preferential 
biodistribution to the liver could be favored by specific 
transport activities driven by transport proteins located 
at the plasma membrane of cystic cholangiocytes.
In summary, we have designed, synthesized, and 
functionally analyzed a family of UDCA synthetic 
conjugates with selective HDAC6 inhibitory activity. 
UDCA-HDAC6i #1 inhibited hepatorenal cystogen-
esis in vivo, improved ciliogenesis in cystic cholan-
giocytes, and inhibited their hyperproliferation. These 
therapeutic effects are superior to the simple sum of 
the individual or combined effects of its constitut-
ing pharmacologically active elements. These UDCA 
synthetic conjugates have preferential targeting to the 
liver through specific BA and organic cation trans-
port properties and are highly concentrated into the 
enterohepatic circulation. These particular features 
make UDCA-HDAC6i molecules especially promis-
ing for the treatment of hepatic and gastrointestinal 
disorders where HDAC6 inhibition is considered a 
therapeutic target, such as acute liver failure, hepa-
tocellular carcinoma, cholangiocarcinoma, pancreatic 
cancer, or colon cancer, among others,(23,41-45) high-
lighting the high degree of translational potential of 
this family of chemical entities.
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